Ann Clin Microbiol.  2024 Dec;27(4):245-255. 10.5145/ACM.2024.27.4.4.

Current nonculture-based diagnosis of candidemia

• Won EJ

• KMID: 2566090
• DOI: http://doi.org/10.5145/ACM.2024.27.4.4

Abstract

Candidemia is the most common healthcare-associated invasive fungal infection with high crude mortality rates. It primarily affects critically ill or severely immunocompromised patients, complicating early diagnosis and prompting the initiation of appropriate antifungal therapy. The gold standard for diagnosing candidemia is blood culture; however, the sensitivity of this test is low and requires at least two days for species identification. These limitations have led to the development of alternative diagnostic methods that are more sensitive and have shorter turnaround times. Here, we review the currently available methods for the nonculturebased diagnosis of candidemia, including (i) immunological diagnostics targeting Candidarelated antigens, (ii) human antibodies to Candida-related antigens, and (iii) molecular diagnostics. The strengths, uses, and limitations of each methodology are discussed. Immunological diagnostics targeting Candida-related antigens and human antibodies to these antigens provide supportive evidence for diagnosing candidemia. Advances in molecular diagnostics have shown promising results in facilitating early candidemia diagnosis, potentially improving patient outcomes.

Keyword

Beta-glucans; Candidemia; Galactomannan; Immunological tests; Molecular diagnostic techniques

Reference

1. Tortorano AM, Prigitano A, Morroni G, Brescini L, Barchiesi F. Candidemia: evolution of drug resistance and novel therapeutic approaches. Infect Drug Resist 2021;14:5543-53.

2. Strollo S, Lionakis MS, Adjemian J, Steiner CA, Prevots DR. Epidemiology of hospitalizations associated with invasive candidiasis, United States, 2002-2012. Emerg Infect Dis 2016;23:713.

3. Koehler P, Stecher M, Cornely OA, Koehler D, Vehreschild M, Bohlius J, et al. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. Clin Microbiol Infect 2019;25:1200-12.

4. Pfaller MA and Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-63.

5. Won EJ, Choi MJ, Jeong SH, Kim D, Shin KS, Shin JH, et al. Nationwide surveillance of antifungal resistance of Candida bloodstream isolates in South Korean hospitals: two year report from Kor-GLASS. J Fungi 2022;8:996.

6. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014;370:1198208.

7. Camp I, Spettel K, Willinger B. Molecular methods for the diagnosis of invasive candidiasis. J Fungi 2020;6:101.

8. Clancy CJ and Nguyen MH. Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 2013;56:1284-92.

9. Clancy CJ and Nguyen MH. Diagnosing invasive candidiasis. J Clin Microbiol 2018;56:101128.

10. Tissot F, Lamoth F, Hauser PM, Orasch C, Fluckiger U, Siegemund M, et al. β-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med 2013;188:1100-9.

11. White SK, Schmidt RL, Walker BS, Hanson KE. (1→3)-β-D-glucan testing for the detection of invasive fungal infections in immunocompromised or critically ill people. Cochrane Database Syst Rev 2020;7:CD009833.

12. Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (1→3)-β-Dglucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005;43:5957-62.

13. Presterl E, Parschalk B, Bauer E, Lassnigg A, Hajdu S, Graninger W. Invasive fungal infections and (1,3)-β-D-glucan serum concentrations in long-term intensive care patients. Int J Infect Dis 2009;13:707-12.

14. Christner M, Abdennadher B, Wichmann D, Kluge S, Pepic A, Aepfelbacher M, et al. The added value of (1,3)-β-D-glucan for the diagnosis of invasive candidiasis in ICU patients: a prospective cohort study. Infection 2024;52:73-81.

15. Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S, et al. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 2012;47:846-54.

16. Tran T and Beal SG. Application of the 1,3-β-D-Glucan (fungitell) assay in the diagnosis of invasive fungal infections. Arch Pathol Lab Med 2016;140:181-5.

17. Du B, Meenu M, Liu H, Xu B. A concise review on the molecular structure and function relationship of β-glucan. Int J Mol Sci 2019;20:4032.

18. Liss B, Cornely OA, Hoffmann D, Dimitriou V, Wisplinghoff H. 1,3-β-D-glucan concentrations in blood products predict false positive post-transfusion results. Mycoses 2016;59:39-42.

19. Usami M, Ohata A, Horiuchi T, Nagasawa K, Wakabayashi T, Tanaka S. Positive (1→3)-β-Dglucan in blood components and release of (1→3)-β-D-glucan from depth-type membrane f ilters for blood processing. Transfusion 2002;42:1189-95.

20. Albert O, Toubas D, Strady C, Cousson J, Delmas C, Vernet V, et al. Reactivity of (1→3)-β-d-glucan assay in bacterial bloodstream infections. Eur J Clin Microbiol Infect Dis 2011;30:1453-60.

21. Shibata N, Kobayashi H, Suzuki S. Immunochemistry of pathogenic yeast, Candida species, focusing on mannan. Proc Jpn Acad Ser B Phys Biol Sci 2012;88:250-65.

22. Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C, Third European Conference on Infections in Leukemia G. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care 2010;14:R222.

23. Held J, Kohlberger I, Rappold E, Busse Grawitz A, Hacker G. Comparison of (1→3)-β-Dglucan, mannan/anti-mannan antibodies, and Cand-Tec Candida antigen as serum biomarkers for candidemia. J Clin Microbiol 2013;51:1158-64.

24. Ellepola AN and Morrison CJ. Laboratory diagnosis of invasive candidiasis. J Microbiol 2005;43:65-84.

25. Sendid B, Caillot D, Baccouch-Humbert B, Klingspor L, Grandjean M, Bonnin A, et al. Contribution of the Platelia Candida-specific antibody and antigen tests to early diagnosis of systemic Candida tropicalis infection in neutropenic adults. J Clin Microbiol 2003;41:4551-8.

26. Fujita SI, Takamura T, Nagahara M, Hashimoto T. Evaluation of a newly developed downf low immunoassay for detection of serum mannan antigens in patients with candidaemia. J Med Microbiol 2006;55:537-43.

27. Jacquinot PM, Plancke Y, Sendid B, Strecker G, Poulain D. Nature of Candida albicansderived carbohydrate antigen recognized by a monoclonal antibody in patient sera and distribution over Candida species. FEMS Microbiol Lett 1998;169:131-8.

28. Rimek D, Singh J, Kappe R. Cross-reactivity of the PLATELIA CANDIDA antigen detection enzyme immunoassay with fungal antigen extracts. J Clin Microbiol 2003;41:3395-8.

29. Cuenca-Estrella M, Verweij PE, Arendrup MC, Arikan-Akdagli S, Bille J, Donnelly JP, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 2012;18(Suppl 7):9-18.

30. Wang K, Luo Y, Zhang W, Xie S, Yan P, Liu Y, et al. Diagnostic value of Candida mannan antigen and anti-mannan IgG and IgM antibodies for Candida infection. Mycoses 2020;63:181-8.

31. Heintz-Buschart A, Eickhoff H, Hohn E, Bilitewski U. Identification of inhibitors of yeast-to-hyphae transition in Candida albicans by a reporter screening assay. J Biotechnol 2013;164:137-42.

32. Wei S, Wu T, Wu Y, Ming D, Zhu X. Diagnostic accuracy of Candida albicans germ tube antibody for invasive candidiasis: systematic review and meta-analysis. Diagn Microbiol Infect Dis 2019;93:339-45.

33. Mizusawa M and Carroll KC. Updates on the profile of GenMark's ePlex blood culture identification fungal pathogen panel. Expert Rev Mol Diagn 2023;23:475-84.

34. Zhang SX, Carroll KC, Lewis S, Totten M, Mead P, Samuel L, et al. Multicenter evaluation of a PCR-based digital microfluidics and electrochemical detection system for the rapid identification of 15 fungal pathogens directly from positive blood cultures. J Clin Microbiol 2020;58:1128.

35. Caliman Sato M, Izu Nakamura Pietro EC, Marques da Costa Alves L, Kramer A, da Silva Santos PS. Candida auris: a novel emerging nosocomial pathogen - properties, epidemiological situation and infection control. GMS Hyg Infect Control 2023;18:Doc18.

36. Price JS, Fallon M, Posso R, Backx M, White PL. An evaluation of the OLM CandID realtime PCR to aid in the diagnosis of invasive candidiasis when testing serum samples. J Fungi 2022;8:935.

37. Fuchs S, Lass-Florl C, Posch W. Diagnostic performance of a novel multiplex PCR assay for candidemia among ICU patients. J Fungi 2019;5:86.

38. Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, et al. Incidence of bloodstream infections due to Candidaz species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004;42:1519-27.

39. Stevenson M, Pandor A, Martyn-St James M, Rafia R, Uttley L, Stevens J, et al. Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi - a systematic review and economic evaluation. Health Technol Assess 2016;20:1-246.

40. Dark P, Blackwood B, Gates S, McAuley D, Perkins GD, McMullan R, et al. Accuracy of LightCycler® SeptiFast for the detection and identification of pathogens in the blood of patients with suspected sepsis: a systematic review and meta-analysis. Intensive Care Med 2015;41:21-33.

41. Denina M, Scolfaro C, Colombo S, Calitri C, Garazzino S, Barbui AM, et al. Erratum to: Magicplex^TM Sepsis Real-Time test to improve bloodstream infection diagnostics in children. Eur J Pediatr 2016;175:1253.

42. Denina M, Scolfaro C, Colombo S, Calitri C, Garazzino S, Barbui AM, et al. MagicplexTM Sepsis Real-Time test to improve bloodstream infection diagnostics in children. Eur J Pediatr 2016;175:1107-11.

43. Salimnia H, Fairfax MR, Lephart PR, Schreckenberger P, DesJarlais SM, Johnson JK, et al. Evaluation of the FilmArray blood culture identification panel: results of a multicenter controlled trial. J Clin Microbiol 2016;54:687-98.

44. Peri AM, Ling W, Furuya-Kanamori L, Harris PNA, Paterson DL. Performance of BioFire Blood Culture Identification 2 Panel (BCID2) for the detection of bloodstream pathogens and their associated resistance markers: a systematic review and meta-analysis of diagnostic test accuracy studies. BMC Infect Dis 2022;22:794. .

45. Park K, Huh JW, Choi SH, Sung H, Kim MN. Clinical evaluation of the T2Candida assay for the rapid diagnosis of candidemia. Diagn Microbiol Infect Dis 2024;110:116406.

46. Clancy CJ and Nguyen MH. T2 magnetic resonance for the diagnosis of bloodstream infections: charting a path forward. J Antimicrob Chemother 2018;73(suppl 4):iv2-5.

47. Blauwkamp TA, Thair S, Rosen MJ, Blair L, Lindner MS, Vilfan ID, et al. Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease. Nat Microbiol 2019;4:663-74.